bcl6 btb

FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).

CID5721353 (BCL6 inhibitor) is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor) that disrupts BCL6 corepressor complexes in vitro and in vivo, and was shown to bind the critical site within the BTB groove.

BI-3812 is an inhibitor of BCL6. Which inhibiting the BTB domain of BCL6 (IC50: 3 nM). BI-3812 also has antitumor activity.

BI-3802, a highly potent BCL6 degrader, targets and inhibits the Bric-à-brac (BTB) domain of BCL6, exhibiting an IC50 value of ≤3 nM. It induces polymerization of BCL6 and facilitates its degradation in a manner dependent on the E3 ligase SIAH1, demonstrating notable antitumor activity[1][2].

SMRT peptide, one of the corepressor factors interacting with the BCL6 BTB domain, binds to the BTB domain of BCL6 to enhance its transcriptional repression function. Additionally, SMRT peptide is utilized for studying protein-protein interactions.